Brief: Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback
07/05/2024 12:49
May 7 (Reuters) - Invivyd Inc IVVD.O :
* COMPANY ANTICIPATES SUBMITTING A COVID-19 TREATMENT EUA
APPLICATION FOR PEMGARDA™ (PEMIVIBART) IMMINENTLY
* INVIVYD LEAVES 2024 NET PRODUCT REVENUE AND YEAR-END CASH
GUIDANCE UNCHANGED
* POTENTIAL NEAR-TERM COVID-19 TREATMENT EUA AND ASSOCIATED
COMMERCIAL DYNAMICS WERE NOT CONSIDERED FOR FY GUIDANCE
Source text for Eikon: ID:nGNX3XJqYC
Further company coverage: IVVD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Invivyd
See all newsBrief: Invivyd Announces Positive Topline Results From Liberty Phase 3 Study Demonstrating Vyd2311 Safety And Tolerability Superior To Mrna-Based Covid-19 Vaccine Announces Regulatory Submission Plans For Vyd2311
Invivyd, Inc. reports results for the quarter ended June 30 - Earnings Summary
Invivyd Q2 loss per share comes wider than expected on higher costs
Brief: Invivyd Q2 EPS USD -0.14
Invivyd, Inc. expected to post a loss of 11 cents a share - Earnings Preview